AVECRIS is addressing one of gene therapy's most difficult challenges: long-lasting, cell-type-specific expression.
AVECRIS has raised $5K in total funding. The most recent round was Grant. The last funding was announced in August 2022.
AVECRIS's investors include First Flight Venture Center, Alameda Research.
AVECRIS is headquartered in Singapore, Singapore.
AVECRIS is addressing one of gene therapy's most difficult challenges: long-lasting, cell-type-specific expression.
AVECRIS is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AVECRIS — Funding & Investors." VCBacked, August 10, 2022, https://www.vcbacked.co/company/avecris. Accessed September 30, 2026.
VCBacked. (2022). AVECRIS — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/avecris
{{cite web |title=AVECRIS — Funding & Investors |url=https://www.vcbacked.co/company/avecris |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated